Literature DB >> 11408737

Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.

A D Santin1, P L Hermonat, A Ravaggi, S Bellone, J J Roman, C V Smith, S Pecorelli, A Radominska-Pandya, M J Cannon, G P Parham.   

Abstract

To investigate and compare the phenotype and function of lymphocytes collected from patients harboring advanced ovarian cancer, leukocytes from peripheral blood (n = 18), ascitic fluid (n = 13) and tumor tissues (n = 13) were evaluated for the relative proportions of lymphocyte subsets, including CD3+, CD4+, CD8+, CD19+, CD56 and the early (CD25) and late (HLA-DR) activation markers on CD3+ T cells. The ability to synthesize type 1 cytokines (IFN-gamma and IL-2) and a type 2 cytokine (IL-4) was assessed by flow cytometry. In all patients, T cells (CD3+) were the major leukocyte population detected in each tissue, with CD4+ T cells being dominant in peripheral blood lymphocytes (PBL) and tumor-associated lymphocytes (TAL) but not in tumor-infiltrating lymphocytes (TIL) (CD4:CD8 ratios: 3.0 vs. 2.0 vs. 1.0, respectively). CD19+ lymphocytes (B cells) and CD56+ lymphocytes (NK cells) were significantly higher in PBL compared to TAL and TIL (p < 0.05). TAL and TIL had a higher proportion of T cells expressing the late activation marker HLA-DR compared to PBL. In contrast, no significant differences were detected in PBL, TAL and TIL in the expression of the early activation marker CD25. Type 1 cytokines were the dominant type produced by in vitro stimulated T cells for each population, with a greater proportion of IFN-gamma+ T cells in TAL and TIL compared to PBL (p < 0.01), and a higher proportion of IL-2+ T cells in PBL compared with TAL and TIL (p < 0.05). Low percentages of IL-4+ T cells (i.e. Th2) were detected in each tissue. Taken together, these data demonstrate the recruitment and accumulation of high concentrations of antigen-experienced T lymphocytes in TAL and TIL compared to PBL. However, low surface expression of IL-2 receptor (i.e. CD25), as well as depressed intracellular IL-2 production in chronically stimulated TAL and TIL suggests that the impaired antitumor function commonly detected in these lymphocyte populations may be secondary to an acquired dysregulation of the IL-2 pathway. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408737     DOI: 10.1159/000058060

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  31 in total

Review 1.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 2.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

Review 3.  Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.

Authors:  Kristin L White; David N Rider; Kimberly R Kalli; Keith L Knutson; Gail P Jarvik; Ellen L Goode
Journal:  Cancer Causes Control       Date:  2011-02-27       Impact factor: 2.506

4.  T cell density and location can influence the prognosis of ovarian cancer.

Authors:  Ahmad Al-Attar; Mohamed Shehata; Lindy Durrant; Paul Moseley; Suha Deen; Stephen Chan
Journal:  Pathol Oncol Res       Date:  2009-12-19       Impact factor: 3.201

5.  Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Authors:  Locke D Uppendahl; Martin Felices; Laura Bendzick; Caitlin Ryan; Behiye Kodal; Peter Hinderlie; Kristin L M Boylan; Amy P N Skubitz; Jeffrey S Miller; Melissa A Geller
Journal:  Gynecol Oncol       Date:  2019-01-15       Impact factor: 5.482

6.  In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

Authors:  Uciane K Scarlett; Juan R Cubillos-Ruiz; Yolanda C Nesbeth; Diana G Martinez; Xavier Engle; Andrew T Gewirtz; Cory L Ahonen; Jose R Conejo-Garcia
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

7.  PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.

Authors:  Wanhua Yang; Peter W Chen; Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02-22       Impact factor: 4.799

8.  Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.

Authors:  Jason R Baird; Barbara A Fox; Kiah L Sanders; Patrick H Lizotte; Juan R Cubillos-Ruiz; Uciane K Scarlett; Melanie R Rutkowski; Jose R Conejo-Garcia; Steven Fiering; David J Bzik
Journal:  Cancer Res       Date:  2013-05-23       Impact factor: 12.701

9.  Monocyte and interferon based therapy for the treatment of ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Christina M Annunziata; Kathryn C Zoon
Journal:  Cytokine Growth Factor Rev       Date:  2016-03-15       Impact factor: 7.638

10.  Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.

Authors:  Yun-Le Wan; Shu-Sen Zheng; Zhi-Cheng Zhao; Min-Wei Li; Chang-Ku Jia; Hao Zhang
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.